Inflammatory status in patients with chronic renal failure: The role of PTX3 and pro-inflammatory cytokines

International Journal of Molecular Medicine

Volumn 20, Issue 4, 2007, Pages 471-481

  Malaponte, Grazia ^a   Libra, Massimo ^a   Bevelacqua, Ylenia ^a   Merito, Paola ^a   Fatuzzo, Pasquale ^a   Rapisarda, Francesco ^a   Cristina, Maria ^a   Naselli, Gabriele ^a   Stivala, Franca ^a   Mazzarino, Maria C ^a   Castellino, Pietro ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

C reactive protein; Cytokines; Fibrinogen; Inflammation; Monocytes; Pentraxin 3

Indexed keywords

AUTACOID; C REACTIVE PROTEIN; CYTOKINE; FIBRINOGEN; LIPOPOLYSACCHARIDE; PENTRAXIN 3; SERUM AMYLOID P;

AGED; ARTICLE; BLOOD; CELL FRACTIONATION; CELL SEPARATION; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FEMALE; HUMAN; INFLAMMATION; MALE; METABOLISM; MONOCYTE; PATHOLOGY; RENAL REPLACEMENT THERAPY; TIME; UREMIA;

AGED; C-REACTIVE PROTEIN; CELL SEPARATION; CYTOKINES; FEMALE; FIBRINOGEN; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; KIDNEY FAILURE, CHRONIC; LIPOPOLYSACCHARIDES; MALE; MONOCYTES; RENAL DIALYSIS; SERUM AMYLOID P-COMPONENT; SUBCELLULAR FRACTIONS; TIME FACTORS; UREMIA;

EID: 38449092677     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.20.4.471     Document Type: Article

References (88)

1. Stenvinkel P: Inflammation in end-stage renal disease - a fire that burns within. Contrib Nephrol 149: 185-199, 2005.
2. Shindler R: Causes and therapy of microinflammation in renal failure. Nephrol Dial Transplant 19 (suppl 5): 34-40, 2004.
3. Ikizler TA, Wingard RL, Harvell J, Shyr Y and Hakim RM: Association of morbidity with markers of nutrition and inflammation in chronic haemodialysis patients: a prospective study. Kidney Int 55: 1945-1951, 1999.
4. Chertow GM, Soroko SH, Paganini EP, Cho KC, Himmelfarb J, Ikizler TA and Mehta RL: Mortality after acute renal failure: Models for prognostic stratification and risk adjustment. Kidney Int 70: 1120-1126, 2006. (Pubitemid 44344083)
5. Amore A and Coppo R: Immunological basis of inflammation in dialysis. Nephrol Dial Transplant 17: 16-24, 2002.
6. Descamps-Latscha B, Herbelin A, Nguyen AT, Jungers P and Chatenoud L: Dysregulation of the immune system in chronic uraemic and hemodialysed patients. Presse Med 24: 405-410, 1995.
7. Girndt M, Sester U, Sester M, Kaul H and Kohler H: Impaired cellular immune function in patients with end-stage renal failure. Nephrol Dial Transplant 14: 2807-2810, 1999.
8. Girndt M, Kaul H, Leitnaker CK, Sester M, Sester U and Kohler H: Selective sequestration of cytokine-producing monocytes during haemodialysis treatment. Am J Kidney Dis 37: 954-963, 2001. (Pubitemid 32436567)
9. Lin YF, Chang DM, Shaio MF, Lu KC, Chyr SH, Li BL and Sheih SD: Cytokine production during haemodialysis: effects of dialytic membrane and complement activation. Am J Nephrol 16: 293-299, 1996.
10. Knerr K, Futh R, Hemsen P, et al: Chronic inflammation and haemodialysis reduce immune competence of peripheral blood leukocytes in end-stage renal failure patients. Cytokine 30: 132-138, 2005. (Pubitemid 40501728)
11. Simmons EM, Himmelfarb J, Sezer MT, et al: Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 65: 1357-1365, 2004. (Pubitemid 38406974)
12. Garibotto G, Sofia A, Procopio V, et al: Peripheral tissue release of interleukin-6 in patients with chronic kidney diseases: Effects of end-stage renal disease and microinflammatory state. Kidney Int 70: 384-390, 2006.
13. Stenvinkel P, Ketteler M, Johnson RJ, et al: IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int 67: 1216-1233, 2005.
14. Lacson E Jr and Levin NW: C-reactive protein and end-stage renal disease. Semin Dial 17: 438-448, 2004.
15. Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340: 448-454, 1999. (Pubitemid 29084777)
16. Kaysen GA: Inflammation: cause of vascular disease and mal-nutrition in dialysis patients. Semin Nephrol 24: 431-436, 2004.
17. Lowrie EG: Acute-phase inflammatory process contributes to malnutrition, anemia, and possibly other abnormalities in dialysis patients. Am J Kidney Dis 32 (suppl 4): 105-112, 1998.
18. Stenvinkel P and Lindholm B: C-reactive protein in end-stage renal disease: are there reasons to measure it? Blood Purif 23: 72-78, 2005.
19. Hutchinson WL, Koenig W, Frohlich M, Sund M, Lowe GD and Pepys MB: Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 46: 934-938, 2000.
20. Vigushin DM, Pepys MB and Hawkins PN: Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 91: 1351-1357, 1993.
21. Kushner I, Jiang SL, Zhang D, Lozanski G and Samols D: Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann NY Acad Sci 762: 102-107, 1995.
22. Campbell B, Badrick T, Flatman R and Kanowski D: Limited clinical utility of high-sensitivity plasma C-reactive protein assays. Ann Clin Biochem 39: 85-88, 2002.
23. Macy EM, Hayes TE and Tracy RP: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 43: 52-58, 1997.
24. Ledue TB and Rifai N: High sensitivity immunoassays for C-reactive protein: promises and pitfalls. Clin Chem Lab Med 39: 1171-1176, 2001.
25. Arici M and Walls J: End-stage renal disease, atherosclerosis, and cardiovascular mortality: is C-reactive protein the missing link? Kidney Int 59: 407-414, 2001.
26. van Tellingen A, Grooteman MP, Schoorl M, et al: Intercurrent clinical events are predictive of plasma C-reactive protein levels in haemodialysis patients. Kidney Int 62: 632-638, 2002.
27. Bottazzi B, Bastone A, Doni A, et al: The long pentraxin PTX3 as a link among innate immunity, inflammation, and female fertility. J Leukoc Biol 79: 909-912, 2006. (Pubitemid 44835576)
28. Goodman AR, Cardozo T, Abagyan R, Altmeyer A, Wisniewski HG and Vilcek J: Long pentraxins: an emerging group of proteins with diverse functions. Cytokine Growth Factor Rev 7: 191-202, 1996.
29. Bottazzi B, Vouret-Craviari V, Bastone A, et al: Multimer formation and ligand recognition by the long pentraxin PTX3. Similarities and differences with the short pentraxins C-reactive protein and serum amyloid P component. J Biol Chem 272: 32817-32823, 1997.
30. Gewurz H, Zhang XH and Lint TF: Structure and function of the pentraxins. Curr Opin Immunol 7: 54-64, 1995.
31. Baumann H and Gauldie J: The acute phase response. Immunol Today 15: 74-80, 1994.
32. Castell JV, Gomez-Lechon MJ, David M, Fabra R, Trullenque R and Heinrich PC: Acute-phase response of human hepatocytes: regulation of acute-phase protein synthesis by interleukin-6. Hepatology 12: 1179-1186, 1990.
33. Introna M, Alles VV, Castellano M, et al: Cloning of mouse ptx3, a new member of the pentraxin gene family expressed at extrahepatic sites. Blood 87: 1862-1872, 1996.
34. Alles VV, Bottazzi B, Peri G, Golay J, Introna M and Mantovani A: Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 84: 3483-3493, 1994.
35. Latini R, Maggioni AP, Peri G, et al: Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation 110: 2349-2354, 2004.
36. Nauta AJ, de Haij S, Bottazzi B, et al: Human renal epithelial cells produce the long pentraxin PTX3. Kidney Int 67: 543-553, 2005.
37. Bussolati B, Peri G, Salvidio G, Verzola D, Mantovani A and Camussi G: The long pentraxin PTX3 is synthesized in IgA glomerulonephritis and activates mesangial cells. J Immunol 170: 1466-1472, 2003. (Pubitemid 36139516)
38. Mantovani A, Garlanda C and Bottazzi B: Pentraxin 3, a non-redundant soluble pattern recognition receptor involved in innate immunity. Vaccine 21 (suppl 2): 43-47, 2003.
39. Vouret-Craviari V, Matteucci C, Peri G, Poli G, Introna M and Mantovani A: Expression of a long pentraxin, PTX3, by monocytes exposed to the mycobacterial cell wall component lipo-arabinomannan. Infect Immun 65: 1345-1350, 1997. (Pubitemid 27146623)
40. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B and Mantovani A: Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med 29: 1404-1407, 2001.
41. Rattazzi M, Faggin E, Bertipaglia B and Pauletto P: Innate immunity and atherogenesis. Lupus 14: 747-751, 2005.
42. Bevelacqua V, Libra M, Mazzarino MC, et al: Long pentraxin 3: A marker of inflammation in untreated psoriatic patients. Int J Mol Med 18: 415-423, 2006.
43. Peri G, Introna M, Corradi D, et al: PTX3, a prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation 102: 636-641, 2000.
44. Malaponte G, Bevelacqua V, Fatuzzo P, Rapisarda F, Emmanuele G, Travali S and Mazzarino MC: IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant 17: 1964-1970, 2002.
45. Rovere P, Peri G, Fazzini F, Bottazzi B, et al: The long pentraxin PTX3 binds to apoptotic cells and regulates their clearance by antigen-presenting dendritic cells. Blood 96: 4300-4306, 2000.
46. Hirschfield GM and Pepys MB: C-reactive protein and cardiovascular disease: new insights from an old molecule. QJM 96: 793-807, 2003. (Pubitemid 37369294)
47. Vanholder R, Van Haecke E, Veys N and Ringoir S: Endotoxin transfer through dialysis membranes: small- versus large-pore membranes. Nephrol Dial Transplant 7: 333-339, 1992.
48. Girndt M, Kohler H, Schiedhelm-Weick E, Schlaak JF, Meyer zum Buschenfelde KH and Fleischer B: Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic haemodialysis patients. Kidney Int 47: 559-565, 1995.
49. Herbelin A, Urena P, Nguyen AT, Zingraff J and Descamps-Latscha B: Influence of first and long-term dialysis on uraemia-associated increased basal production of interleukin-1 and tumour necrosis factor alpha by circulating monocytes. Nephrol Dial Transplant 6: 349-357, 1991.
50. Naumovic RT, Djukanovic LD, Ramic ZD and Ostric VZ: Relationship between IL-1beta and TNFalpha production by PBMC and clinical features of haemodialysis patients. Ren Fail 22: 195-204, 2000.
51. Nisbeth U, Hallgren R, Eriksson O and Danielson BG: Endotoxemia in chronic renal failure. Nephron 45: 93-97, 1987.
52. Sundaram S, Barrett TW, Meyer KB, Perrella C, Neto MC, King AJ and Pereira BJ: Transmembrane passage of cytokine-inducing bacterial products across new and reprocessed polysulfone dialyzers. J Am Soc Nephrol 7: 2183-2191, 1996. (Pubitemid 27468248)
53. Higuchi T, Fukuda N, Yamamoto C, et al: The influence of uraemic serum on interleukin-1beta and interleukin-1 receptor antagonist production by peripheral blood mononuclear cells. Ther Apher Dial 10: 65-71, 2006.
54. Powell AC, Bland LE, Oettinger CW, McAllister SK, Oliver JC, Arduino MJ and Favero MS: Lack of plasma interleukin-1 beta or tumor necrosis factor-alpha elevation during unfavorable haemodialysis conditions. J Am Soc Nephrol 2: 1007-1013, 1991.
55. Blumenstein M, Schmidt B, Ward RA, et al: Altered interleukin-1 production in patients undergoing haemodialysis. Nephron 50: 277-281, 1988.
56. Pereira BJ, Poutsiaka DD, King AJ, Strom JA, Narayan G, Levey AS and Dinarello CA: In vitro production of interleukin-1 receptor antagonist in chronic renal failure, CAPD and HD. Kidney Int 42: 1419-1424, 1992.
57. Tarakcioglu M, Erbagci AB, Usalan C, Deveci R and Kocabas R: Acute effect of haemodialysis on serum levels of the pro-inflammatory cytokines. Mediators Inflamm 12: 15-19, 2003. (Pubitemid 36566700)
58. Friedlander MA, Hilbert CM, Wu YC and Rich EA: Role of dialysis modality in responses of blood monocytes and peritoneal macrophages to endotoxin stimulation. Am J Kidney Dis 22: 11-23, 1993.
59. Zaoui P and Hakim RM: The effects of the dialysis membrane on cytokine release. J Am Soc Nephrol 4: 1711-1718, 1994.
60. Tzanatos HA, Agroyannis B, Chondros C, Kapetanaki A, Fourtounas C, Soubassi L and Kopelias I: Cytokine release and serum lipoprotein (a) alterations during haemodialysis. Artif Organs 24: 329-333, 2000.
61. Guth HJ, Gruska S and Kraatz G: The measurement of cytokine production capacity during dialysis - a new dynamic method for the evaluation of biocompatibility? Int J Artif Organs 23: 675-679, 2000.
62. Mege JL, Olmer M, Purgus R, et al: Haemodialysis membranes modulate chronically the production of TNF alpha, IL1beta and IL6. Nephrol Dial Transplant 6: 868-875, 1991.
63. Varela MP, Kimmel PL, Phillips TM, Mishkin GJ, Lew SQ and Bosch JP: Biocompatibility of haemodialysis membranes: interrelations between plasma complement and cytokine levels. Blood Purif 19: 370-379, 2001.
64. Cassidy MJ, De Jager C, Ebrahim O, Camachio P and Robson S: Peripheral blood mononuclear cells from patients with chronic renal failure release factors which suppress erythropoietin secretion in vitro. Nephrol Dial Transplant 9: 775-779, 1994.
65. Mackiewicz A, Speroff T, Ganapathi MK and Kushner I: Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146: 3032-3037, 1991.
66. Rocco MV, Paranandi L, Burrowes JD, et al: Nutritional status in the HEMO Study cohort at baseline. Haemodialysis. Am J Kidney Dis 39: 245-256, 2002. (Pubitemid 34174246)
67. Kalantar-Zadeh K, Stenvinkel P, Pillon L and Kopple JD: Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 10: 155-169, 2003.
68. Kaysen GA, Dubin JA, Muller HG, Mitch WE, Rosales L and Levin NW: HEMO Group: Impact of albumin synthesis rate and the acute phase response in the dual regulation of fibrinogen levels in haemodialysis patients. Kidney Int 63: 315-322, 2003.
69. Giordano M, De Feo P, Lucidi P, et al: Increased albumin and fibrinogen synthesis in haemodialysis patients with normal nutritional status. J Am Soc Nephrol 12: 349-354, 2001.
70. Fazzini F, Peri G, Doni A, et al: PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum 44: 2841-2850, 2001.
71. Irish A: Cardiovascular disease, fibrinogen and the acute phase response: associations with lipids and blood pressure in patients with chronic renal disease. Atherosclerosis 137: 133-139, 1998.
72. Ernst E: Fibrinogen: an important risk factor for atherothrombotic diseases. Ann Med 26: 15-22, 1994.
73. Klouche M, Peri G, Knabbe C, Eckstein HH, Schmid FX, Schmitz G and Mantovani A: Modified atherogenic lipoproteins induce expression of pentraxin-3 by human vascular smooth muscle cells. Atherosclerosis 175: 221-228, 2004. (Pubitemid 38942901)
74. Napoleone E, Di Santo A, Bastone A, et al: Long pentraxin PTX3 upregulates tissue factor expression in human endothelial cells: a novel link between vascular inflammation and clotting activation. Arterioscler Thromb Vasc Biol 22: 782-787, 2002. (Pubitemid 34517789)
75. Rolph MS, Zimmer S, Bottazzi B, et al: Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 22: 10-14, 2002.
76. Lee GW, Goodman AR, Lee TH and Vilcek J: Relationship of TSG-14 protein to the pentraxin family of major acute phase proteins. J Immunol 153: 3700-3707, 1994.
77. Borish LC and Steinke JW: Cytokines and chemokines. J Allergy Clin Immunol 111: S460-S475, 2003.
78. Panichi V, Tetta C, Rindi P, Palla R and Lonnemann G: Plasma C-reactive protein is linked to backfiltration associated interleukin- 6 production. ASAIO J 44: M415-M417, 1998.
79. Memoli B, Minutolo R, Bisesti V, et al: Changes of serum albumin and C-reactive protein are related to changes of interleukin-6 release by peripheral blood mononuclear cells in haemodialysis patients treated with different membranes. Am J Kidney Dis 39: 266-273, 2002.
80. Honkanen E, Gronhagen-Riska C, Teppo AM, Maury CP and Meri S: Acute-phase proteins during haemodialysis: correlations with serum interleukin-1beta levels and different dialysis membranes. Nephron 57: 283-287, 1991.
81. Pasceri V, Willerson JT and Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000.
82. Yeun JY, Levine RA, Mantadilok V and Kaysen GA: C-reactive protein predicts all-cause and cardiovascular mortality in haemodialysis patients. Am J Kidney Dis 35: 469-476, 2000.
83. Lee WY, Allison MA, Kim DJ, Song CH and Barrett-Connor E: Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). Am J Cardiol 99: 99-102, 2007.
84. Mortensen RF: C-reactive protein, inflammation, and innate immunity. Immunol Res 24: 163-176, 2001.
85. Nauta AJ, Daha MR, van Kooten C and Roos A: Recognition and clearance of apoptotic cells: a role for complement and pentraxins. Trends Immunol 24: 148-154, 2003.
86. Roumenina LT, Ruseva MM, Zlatarova A, et al: Interaction of C1q with IgG1, C-reactive protein and pentraxin 3: mutational studies using recombinant globular head modules of human C1q A, B, and C chains. Biochemistry 45: 40093-40104, 2006.
87. Chang MK, Binder CJ, Torzewski M and Witztum JL: C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids. Proc Natl Acad Sci USA 99: 13043-13048, 2002.
88. Calabro P, Willerson JT and Yeh ET: Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108: 1930-1932, 2003.